ATE375786T1 - Chitin-mikropartikel und ihre medizinische verwendung - Google Patents

Chitin-mikropartikel und ihre medizinische verwendung

Info

Publication number
ATE375786T1
ATE375786T1 AT02758543T AT02758543T ATE375786T1 AT E375786 T1 ATE375786 T1 AT E375786T1 AT 02758543 T AT02758543 T AT 02758543T AT 02758543 T AT02758543 T AT 02758543T AT E375786 T1 ATE375786 T1 AT E375786T1
Authority
AT
Austria
Prior art keywords
medical use
chitin microparticles
gamma
treatment
chitin
Prior art date
Application number
AT02758543T
Other languages
English (en)
Inventor
Peter Strong
Original Assignee
Cmp Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0120030A external-priority patent/GB0120030D0/en
Priority claimed from GB0206864A external-priority patent/GB0206864D0/en
Application filed by Cmp Therapeutics Ltd filed Critical Cmp Therapeutics Ltd
Application granted granted Critical
Publication of ATE375786T1 publication Critical patent/ATE375786T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Pulmonology (AREA)
  • Otolaryngology (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Materials For Medical Uses (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AT02758543T 2001-08-16 2002-08-16 Chitin-mikropartikel und ihre medizinische verwendung ATE375786T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0120030A GB0120030D0 (en) 2001-08-16 2001-08-16 Chitin Microparticles and their medical uses
GB0206864A GB0206864D0 (en) 2002-03-22 2002-03-22 Chitin microparticles and their medical uses

Publications (1)

Publication Number Publication Date
ATE375786T1 true ATE375786T1 (de) 2007-11-15

Family

ID=26246442

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02758543T ATE375786T1 (de) 2001-08-16 2002-08-16 Chitin-mikropartikel und ihre medizinische verwendung

Country Status (11)

Country Link
US (2) US7498038B2 (de)
EP (1) EP1416916B1 (de)
JP (1) JP2005501845A (de)
CN (1) CN1543338B (de)
AT (1) ATE375786T1 (de)
AU (1) AU2002324124B2 (de)
CA (1) CA2457027C (de)
DE (1) DE60223037T2 (de)
ES (1) ES2295391T3 (de)
PT (1) PT1416916E (de)
WO (1) WO2003015744A1 (de)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2001491B1 (de) 2006-04-05 2016-06-08 Yissum Research Development Company of the Hebrew University of Jerusalem Ltd. Antiallergische zusammensetzungen
US20080014281A1 (en) * 2006-06-16 2008-01-17 Florida Atlantic University Chitin Micro-Particles As An Adjuvant
EP2026820A1 (de) 2006-06-20 2009-02-25 CMP Therapeutics Limited Zusammensetzungen mit chitin-mikroteilchen und ihre medizinische anwendung
IL178495A (en) * 2006-10-05 2014-12-31 Univ Ben Gurion Use of cancerous gastric components or artificial calcium containing carbonate, chitin and polypeptide preparations to treat calcium metabolism-related or calcium-signaling conditions
CN101563065A (zh) * 2006-10-30 2009-10-21 Cmp医疗有限公司 制备微粒的方法
CN100531742C (zh) * 2007-01-18 2009-08-26 宁波普爱生物工程有限公司 一种抗肿瘤氨基多糖超细微粒及其制备方法
EP2123261A1 (de) 2008-05-20 2009-11-25 Stallergenes S.A. Speichelklebende Partikelformulierung zur Induzierung von antigenspezifischer Immuntoleranz
WO2010014827A2 (en) * 2008-07-30 2010-02-04 Stc.Unm Formulations containing large-size carrier particles for dry powder inhalation aerosols
US9005899B2 (en) * 2010-04-01 2015-04-14 Mingchi University Of Technology Chitin-induced immune response based method for diagnosing allergic asthma in patients
WO2011135578A1 (en) * 2010-04-28 2011-11-03 Chetan Balar Composition comprising chitin and tinosporin for use in the treatment of viral diseases
WO2012022947A1 (en) 2010-08-17 2012-02-23 Cmp Therapeutics Limited Nutritional compositions comprising chitin microparticles
US9259357B2 (en) 2014-04-16 2016-02-16 Loma Linda University Composition, preparation, and use of chitosan shards for biomedical applications
CN107921061A (zh) 2015-06-04 2018-04-17 艾玛菲克有限公司 用聚磷酸/聚磷酸酯/聚磷酸盐或双膦酸/双膦酸酯/双膦酸盐稳定的无定形碳酸钙
US11686733B2 (en) 2016-05-13 2023-06-27 Applied Medical Enzyme Research Institute Corporation Method for collecting data to predict risk of developing allergies
IL294615A (en) 2016-10-25 2022-09-01 Amorphical Ltd Amorphous calcium carbonate for treating a leukemia
WO2021014448A1 (en) 2019-07-23 2021-01-28 Amorphical Ltd Amorphous calcium carbonate for improving athletic performance
CN117377878A (zh) 2021-04-01 2024-01-09 贝克顿·迪金森公司 提高a族链球菌免疫测定特异性和灵敏度的方法

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5543041A (en) * 1978-09-25 1980-03-26 Eisai Co Ltd Immunity raising agent
JPS5927826A (ja) * 1982-08-10 1984-02-14 Masuko Suzuki 抗感染症剤
CA1261264A (en) * 1984-11-29 1989-09-26 Shigeo Suzuki Immunopotentiating agents and method
US5811128A (en) * 1986-10-24 1998-09-22 Southern Research Institute Method for oral or rectal delivery of microencapsulated vaccines and compositions therefor
US4873092A (en) 1987-05-21 1989-10-10 Murata Kikai Kabushiki Kaisha Slow-releasing preparation
US5690954A (en) 1987-05-22 1997-11-25 Danbiosyst Uk Limited Enhanced uptake drug delivery system having microspheres containing an active drug and a bioavailability improving material
GB8904370D0 (en) 1989-02-25 1989-04-12 Cosmas Damian Ltd Liquid delivery compositions
GB9202464D0 (en) 1992-02-05 1992-03-18 Danbiosyst Uk Composition for nasal administration
US5292513A (en) * 1992-05-18 1994-03-08 Anthony G. Gristina Method for nonspecific cellular immune stimulation
JP2824185B2 (ja) * 1993-03-22 1998-11-11 旭化成工業株式会社 魚類免疫賦活剤
JPH07188291A (ja) * 1993-12-27 1995-07-25 Hayashibara Biochem Lab Inc 蛋白質とその製造方法並びに用途
JPH0959164A (ja) * 1995-08-21 1997-03-04 San Five Kk 抗炎症剤
GB9525083D0 (en) * 1995-12-07 1996-02-07 Danbiosyst Uk Vaccine compositions
WO2002089839A1 (en) 2001-05-03 2002-11-14 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Intranasal immunization with detoxified lipooligosaccharide from nontypeable haemophilus influenzae or moraxella catarrhalis
DE69712110T2 (de) 1996-07-10 2002-12-12 West Pharmaceutical Services Drug Delivery & Clinical Research Centre Ltd., Nottingham Zusammensetzungen zur einführung von genen in epithelzellen
US6465016B2 (en) 1996-08-22 2002-10-15 Research Triangle Pharmaceuticals Cyclosporiine particles
GB9700624D0 (en) 1997-01-14 1997-03-05 Danbiosyst Uk Drug delivery composition
JP4097737B2 (ja) * 1997-04-07 2008-06-11 ユニチカ株式会社 鼻口腔用抗炎症散布剤
GB9713980D0 (en) 1997-07-03 1997-09-10 Danbiosyst Uk New conjugates
EP1035833B1 (de) 1997-12-02 2005-08-31 Archimedes Development Limited Zusammensetzungen zur nasalen verabreichung
GB9800912D0 (en) 1998-01-17 1998-03-11 Danbiosyst Uk New composition
PL343438A1 (en) * 1998-04-08 2001-08-13 Lilly Co Eli Pulmonary and nasal delivery of raloxifene
EP1113818B1 (de) * 1998-09-18 2006-05-17 Dynavax Technologies Corporation Verfahren zur behandlung von ig-e assozierten krankheiten und zusammensetzungen zur verwendung in diesen verfahren
ES2311451T3 (es) 1999-03-24 2009-02-16 The Secretary Of State For Defence Carbohidratos policationicos como immuestimulantes en vacunas.
KR100345466B1 (ko) 1999-10-08 2002-07-26 한국과학기술연구원 콜레라 독소 ｂ 소단위로 표면 수식된 마이크로스피어
US6764685B1 (en) * 2000-03-21 2004-07-20 Medimmune Vaccines, Inc. Recombinant parainfluenza virus expression systems and vaccines
US20020106368A1 (en) 2000-07-28 2002-08-08 Adrian Bot Novel methods and compositions to upregulate, redirect or limit immune responses to peptides, proteins and other bioactive compounds and vectors expressing the same
US6773695B2 (en) 2000-10-05 2004-08-10 Mannkind Corporation Modulation of allergic response
WO2002034287A2 (en) 2000-10-27 2002-05-02 Pharmexa A/S Therapeutic vaccine formulations containing chitosan
AU2003229667A1 (en) 2002-04-18 2003-10-27 Akzo Nobel N.V. Antigen-loaded chitosan microparticles for oral vaccination
US20050013812A1 (en) 2003-07-14 2005-01-20 Dow Steven W. Vaccines using pattern recognition receptor-ligand:lipid complexes
EP2026820A1 (de) * 2006-06-20 2009-02-25 CMP Therapeutics Limited Zusammensetzungen mit chitin-mikroteilchen und ihre medizinische anwendung

Also Published As

Publication number Publication date
US20040234614A1 (en) 2004-11-25
DE60223037D1 (de) 2007-11-29
US8551501B2 (en) 2013-10-08
PT1416916E (pt) 2008-01-25
CA2457027C (en) 2011-10-11
EP1416916B1 (de) 2007-10-17
AU2002324124B2 (en) 2007-01-04
JP2005501845A (ja) 2005-01-20
CN1543338A (zh) 2004-11-03
US7498038B2 (en) 2009-03-03
DE60223037T2 (de) 2008-07-24
WO2003015744A1 (en) 2003-02-27
CA2457027A1 (en) 2003-02-27
ES2295391T3 (es) 2008-04-16
EP1416916A1 (de) 2004-05-12
CN1543338B (zh) 2010-06-16
US20090214666A1 (en) 2009-08-27

Similar Documents

Publication Publication Date Title
DE60223037D1 (de) Chitin-mikropartikel und ihre medizinische verwendung
DK1261360T3 (da) Casein-afledte peptider og anvendelser deraf i behandling
WO2005081628A3 (en) Casein derived peptides and therapeutic uses thereof
DE60327999D1 (de) Azolylaminoazine als inhibitoren von proteinkinasen
IL184749A0 (en) Anti-interferon gamma antibodies and pharmaceutical compositions containing the same
DK1556021T3 (da) Farmaceutiske sammensætninger omfattende flavonoider og menthol samt fremgangsmåder til behandling med brug af nævnte sammensætninger
MXJL05000010A (es) Compuestos de fenil-aza-benzimidazol para modular la ige e inhibir la proliferacion celular.
CY1110727T1 (el) Παρασκευασματα θετικων κατα gram βακτηριων για τη θεραπεια ασθενειων που περιλαμβανουν μια ανοσολογικη δυσρυθμιση
MXJL05000009A (es) Compuestos de fenilindon para modular la ige e inhibir la proliferacion celular.
NO20064192L (no) Agonister og antagonister av P28, EB13 og WSX/TCCR til behandling av immunforstyrrelser
DE602004017332D1 (de) Neue kondensierte n-pyrazinyl-sulfonamide und deren verwendung bei der behandlung von chemokinvermittelten krankheiten
DK1675603T3 (da) Anvendelse af probiotiske bakterier i behandling af infektion
KR20040078639A (ko) 카세인 유도 펩타이드 및 이들의 치료 용도
DE602004025689D1 (de) Antivirale mittel zur behandlung, kontrolle und prävention von infektionen durch coronaviren
FR2842422B1 (fr) Compositions destinees au traitement des neuropathies peripheriques, preparation et utilisations
DE602004019541D1 (de) Cycloalkyläbü kondensierte indole
DE602004009414D1 (de) BEHANDLUNG VON GASTROINTESTINALEN ERKRANKUNGEN MIT N-2,3,3-TETRAMETHYLBICYCLOi2.2.1öHEPTAN-2-AMINE
EP1675549A4 (de) Geschulte nkt-zellen und ihre verwendungen in der behandlung von immunstörungen
ATE431399T1 (de) Verwendung von cytokinen, zellen und mitogene zur hemmung der graft-versus-host krankheit
EA200600314A1 (ru) Использование растворимого cd164 при воспалительных и/или аутоимунных нарушениях
ATE544453T1 (de) Kombinationstherapien mit l-fmau zur behandlung von hepatitis-b-virus-infektionen
DE60134408D1 (de) Für akzessorische hiv proteine kodierende dna impfstoffe
ATE410235T1 (de) Behandlung von ballastwasser
ATE386542T1 (de) Mittel zur stimulation des immunsystems
ATE390144T1 (de) Behandlung von fibrosen